Editorial Commentary
Letter to the Editor
Are metastatic central lymph nodes (D3 volume) in right-sided colon cancer “REALLY” a sign of systemic disease?—a sub-group analysis of an ongoing multicenter trial
AME Clinical Trials Review
2024;
2:
91
(25 October 2024)
Editorial Commentary
One more point for ibrutinib plus rituximab over fludarabine, cyclophosphamide and rituximab (FCR)
AME Clinical Trials Review
2024;
2:
90
(25 October 2024)
Editorial Commentary
The optimum balance between efficacy and toxicity with different doses of trastuzumab deruxtecan in HER2 mutated non-small cell lung cancer in DESTINY-Lung02 trial
AME Clinical Trials Review
2024;
2:
89
(25 October 2024)
Editorial Commentary
Advancing hepatocellular carcinoma treatment: a triple combination for patients with extrahepatic metastasis—better or bust?
AME Clinical Trials Review
2024;
2:
88
(25 October 2024)
Editorial Commentary
Teamwork makes the dream work?—dissecting the role of triple therapy: radiotherapy combined with sintilimab plus bevacizumab for hepatocellular carcinoma and malignant portal vein invasion
AME Clinical Trials Review
2024;
2:
87
(25 October 2024)
Editorial Commentary
A new ALK inhibitor is not a game changer, but an older one is!
AME Clinical Trials Review
2024;
2:
86
(25 October 2024)
Editorial Commentary
Utilizing therapeutic response as a criterion for PARP inhibitor maintenance therapy in advanced triple negative breast cancer; promoting personalized medicine
AME Clinical Trials Review
2024;
2:
85
(25 October 2024)
Editorial Commentary
Open surgery may no longer be a control arm of minimally invasive surgery for gastric cancer
AME Clinical Trials Review
2024;
2:
84
(25 October 2024)
Editorial Commentary
Tislelizumab: a promising alternative first-line systemic therapy in unresectable advanced hepatocellular carcinoma
AME Clinical Trials Review
2024;
2:
83
(25 October 2024)
Editorial Commentary
Adding pieces to immunotherapy puzzle in biliary tract cancer
AME Clinical Trials Review
2024;
2:
82
(25 October 2024)
Editorial Commentary
Panning for gold in a dry creek?—the ongoing search for role of immunotherapy in mismatch repair proficient rectal cancer
AME Clinical Trials Review
2024;
2:
81
(25 October 2024)
Editorial Commentary
Peposertib as a radiosensitizing agent in the treatment of locally advanced rectal cancer
AME Clinical Trials Review
2024;
2:
80
(25 October 2024)
Editorial Commentary
Mechanical and oral antibiotic bowel prep should be standard before elective rectal resection
AME Clinical Trials Review
2024;
2:
79
(25 October 2024)
Editorial Commentary
TARMAC trial—a new path for chimeric antigen receptor (CAR) T in relapsed mantle cell lymphoma (MCL)?
AME Clinical Trials Review
2024;
2:
78
(25 October 2024)
Editorial Commentary
Synergising hypomethylating agents with immunotherapy in renal cell carcinoma: unlocking the potential of an old classic
AME Clinical Trials Review
2024;
2:
77
(25 October 2024)
Editorial Commentary
Targeting the TGF-β pathway in patients with non-small cell lung cancer
AME Clinical Trials Review
2024;
2:
76
(25 October 2024)
Editorial Commentary
The ‘right’ timing for durvalumab after chemoradiation in stage III non-small cell lung cancer
AME Clinical Trials Review
2024;
2:
75
(25 October 2024)
Editorial Commentary
Beyond the PARP inhibition: what is the future of ovarian cancer treatment?
AME Clinical Trials Review
2024;
2:
74
(25 October 2024)
Editorial Commentary
What is the role of perioperative immunotherapy and chemotherapy in stage III resectable non-small cell lung cancer?
AME Clinical Trials Review
2024;
2:
73
(25 October 2024)
Editorial Commentary
Progress in the integration of radiation therapy and checkpoint inhibition in hepatocellular carcinoma
AME Clinical Trials Review
2024;
2:
72
(25 October 2024)
Editorial Commentary
To fast or not to fast—that is the question?
Editorial Commentary
What is the role of consolidation immunotherapy after chemoradiotherapy in stage III EGFR-mutant non-small cell lung cancer?
Published online: 20 October 2023
Editorial Commentary
The immune “tsunami” has arrived at the shores of early-stage non-small cell lung cancer
Published online: 06 September 2023
Editorial Commentary
The Butterfly effect—will the MARIPOSA-2 study alter the trajectory of EGFR mutated non-small cell lung cancer (NSCLC)
Published online: 06 June 2024
Editorial Commentary
ADAURA: redefining the role of target therapy in resectable lung adenocarcinoma
Published online: 09 April 2024
Editorial Commentary
The opening gambit: CheckMate 159 and the immunotherapy neoadjuvant era in non-small cell lung cancer
Published online: 24 November 2023
Editorial
Advancing the understanding, reflection, and translation of clinical trials: inaugural editorial to AME Clinical Trials Review
Published online: 31 May 2023
Editorial Commentary
Is osimertinib effective as 2nd line treatment in T790M-negative EGFR mutant NSCLC?
Published online: 09 April 2024
Editorial Commentary
EMPOWER Lung-3 Part 2: empowering options for anti-PD-1 and chemotherapy in non-small cell lung cancer with current landscape and remaining challenges
Published online: 18 December 2023
Editorial Commentary
KEYNOTE-189 5-years update: setting a backbone for the next generation clinical research in advanced non-squamous non-small cell lung cancer without oncogenic addiction
Published online: 11 June 2024
Editorial Commentary
Xaluritamig: a first step towards a new target, new mechanism for metastatic prostate cancer
Published online: 15 August 2024
Editorial Commentary
The third-generation EGFR TKI osimertinib could be a promising neoadjuvant therapy in patients with resectable EGFR-mutant NSCLC
Published online: 01 February 2024
Editorial Commentary
Improving the efficacy of immunotherapy in patients with advanced or metastatic urothelial carcinoma: a new role for tyrosine kinase inhibitors in the treatment paradigm?
Published online: 18 June 2024
Editorial Commentary
Utilization of pharmacokinetics in the dosing of pembrolizumab in non-small cell lung cancer
Published online: 29 January 2024
Editorial Commentary
Neoadjuvant osimertinib: a promising therapeutic option for locally advanced EGFR-mutant lung adenocarcinoma
Published online: 27 March 2024
Editorial Commentary
Towards better outcomes: segmentectomy for ground-glass opacity-dominant non-small cell lung cancer 3 cm or less—insights from JCOG1211
Published online: 07 October 2023
Editorial Commentary
Targeting TIGIT in lung cancer: will it stick to the wall?
Published online: 21 June 2024
Editorial Commentary
NEOSTAR platform trial: neoadjuvant dual immunotherapy plus chemotherapy—more is better?
Published online: 02 February 2024
Editorial Commentary
Optimizing the role of immunotherapy in the management of resectable non-small cell lung cancer
Published online: 03 February 2024
Editorial Commentary
Changing the way we treat KRAS G12C non-small cell lung cancers
Published online: 18 January 2024
Editorial Commentary
